Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020

Rhea-AI Summary

Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter 2020 financial results on July 30, 2020, prior to the U.S. market opening. Following the announcement, management will conduct a conference call at 8:30 AM ET to discuss the results and provide a corporate update. Investors can join the call via telephone or through a live webcast on Compugen's website. The company focuses on cancer immunotherapy, with lead candidates COM701 and COM902 currently in Phase 1 clinical studies.

Positive

• Lead drug candidates COM701 and COM902 are advancing in Phase 1 clinical trials.

Negative

• None.

HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-888-407-2553 from the U.S.,
or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972-(3)-765-8124

Investor Relations contact:
Bob Yedid
LifeSci Advisors, LLC
Email: bob@lifesciadvisors.com
Tel: +1-(646)-597-6989

Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: jo@lifescicomms.com
Tel: +1-(646)-751-4361

View original content:http://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2020-results-on-thursday-july-30-2020-301094676.html

SOURCE Compugen Ltd.

FAQ

When will Compugen release its Q2 2020 financial results?

Compugen will release its Q2 2020 financial results on July 30, 2020.

What time is the Compugen Q2 2020 results conference call?

The conference call for Compugen's Q2 2020 results is scheduled for 8:30 AM ET.

How can I access the Compugen Q2 2020 financial results call?

You can access the call by dialing 1-888-407-2553 from the U.S. or +972-3-918-0610 internationally, or via a live webcast on Compugen's website.

What are the main products in Compugen's pipeline?

Compugen's main products include COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT, both in Phase 1 studies.